Early identification of high-risk individuals for monoclonal antibody therapy and prophylaxis is feasible by SARS-CoV-2 anti-spike antibody specific lateral flow assay
Author(s)
Type
Journal Article
Abstract
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30-59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.
Date Issued
2022-11-01
Date Acceptance
2022-08-06
Citation
Diagnostic Microbiology and Infectious Disease, 2022, 104 (3)
ISSN
0732-8893
Publisher
Elsevier
Journal / Book Title
Diagnostic Microbiology and Infectious Disease
Volume
104
Issue
3
Copyright Statement
© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
(http://creativecommons.org/licenses/by/4.0/)
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/36084423
PII: S0732-8893(22)00154-7
Subjects
COVID-19
Lateral flow assay
Monoclonal antibody
Adult
Antibodies, Monoclonal
Antibodies, Viral
COVID-19
Female
Humans
Immunoglobulin G
Immunoglobulin M
Male
SARS-CoV-2
Publication Status
Published
Coverage Spatial
United States
Article Number
ARTN 115788
Date Publish Online
2022-08-12